Medidata Solutions (NASDAQ:MDSO) – Dougherty & Co issued their Q2 2018 earnings per share estimates for Medidata Solutions in a research note issued to investors on Sunday, April 22nd. Dougherty & Co analyst G. Mannheimer anticipates that the company will post earnings per share of $0.22 for the quarter.
MDSO has been the topic of several other research reports. Zacks Investment Research cut Medidata Solutions from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. BidaskClub upgraded Medidata Solutions from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Morgan Stanley decreased their price objective on Medidata Solutions from $86.00 to $79.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. Needham & Company LLC raised their price objective on Medidata Solutions to $80.00 and gave the stock a “buy” rating in a report on Friday, April 20th. Finally, ValuEngine cut Medidata Solutions from a “hold” rating to a “sell” rating in a report on Saturday, March 17th. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $82.71.
MDSO stock opened at $70.92 on Tuesday. Medidata Solutions has a 52-week low of $59.60 and a 52-week high of $85.92. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.49 and a current ratio of 1.63. The firm has a market cap of $4,329.75, a PE ratio of 83.44, a price-to-earnings-growth ratio of 3.87 and a beta of 1.53.
Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings data on Thursday, April 19th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.05. Medidata Solutions had a return on equity of 11.36% and a net margin of 7.96%. The business had revenue of $149.20 million for the quarter, compared to analysts’ expectations of $146.73 million. During the same quarter last year, the firm earned $0.31 earnings per share. The business’s revenue was up 16.9% on a year-over-year basis.
In other news, CFO Rouven Bergmann sold 2,000 shares of Medidata Solutions stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $67.47, for a total transaction of $134,940.00. Following the sale, the chief financial officer now directly owns 82,775 shares of the company’s stock, valued at $5,584,829.25. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Tarek Sherif sold 26,836 shares of Medidata Solutions stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $70.25, for a total value of $1,885,229.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 34,836 shares of company stock worth $2,438,769. Corporate insiders own 5.80% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in MDSO. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Medidata Solutions by 48.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,242 shares of the company’s stock worth $205,000 after acquiring an additional 1,056 shares during the last quarter. Meadow Creek Investment Management LLC increased its position in shares of Medidata Solutions by 31.4% during the fourth quarter. Meadow Creek Investment Management LLC now owns 3,680 shares of the company’s stock worth $233,000 after acquiring an additional 880 shares during the last quarter. Polen Capital Management LLC increased its position in shares of Medidata Solutions by 77.0% during the fourth quarter. Polen Capital Management LLC now owns 4,640 shares of the company’s stock worth $294,000 after acquiring an additional 2,018 shares during the last quarter. Brown Advisory Securities LLC purchased a new stake in shares of Medidata Solutions during the fourth quarter worth about $356,000. Finally, Elkfork Partners LLC purchased a new stake in shares of Medidata Solutions during the fourth quarter worth about $408,000.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/04/25/analysts-set-expectations-for-medidata-solutions-q2-2018-earnings-mdso.html.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.